FLUVESTRANT IN A DOSAGE OF 500 MG FOR THE TREATMENT OF ADVANCED BREAST CANCER

• 1. 治疗HER2阳性局部晚期或先前未治疗的转移性乳腺癌的方法 [P] . 中国专利： CN107614015A . 2018-01-19
• 2. 晚期三阴性乳腺癌铂类治疗敏感性的预测指标生成分析方法 [P] . 中国专利： CN113981080A . 2022-01-28
• 3. FLUVESTRANT IN A DOSAGE OF 500MG FOR THE TREATMENT OF ADVANCED BREAST CANCER [P] . HU1200203A3 . 2012-12-28

  机译： 以500毫克的剂量来治疗高级乳腺癌

• 4. FLUVESTRANT IN A DOSAGE OF 500MG FOR THE TREATMENT OF ADVANCED BREAST CANCER [P] . HU1200203A2 . 2012-09-28

  机译： 以500毫克的剂量来治疗高级乳腺癌

• 5. FULVESTRANT IN A DOSAGE OF 500 MG FOR THE TREATMENT OF ADVANCED BREAST CANCER [P] . LT5953B . 2013-07-25

  机译： 剂量为500 MG的强效药物治疗晚期乳腺癌

• 1. Chidamide Combined with Paclitaxel Liposome for the Treatment of Advanced HER2-negative Breast Cancer in Clinical Study [J] . Ichrak Ben Abdallah, Mehmet Sitki Copur 现代肿瘤学研究进展(英文) . 2019,第005期
• 2. Clinical Efficacy and Safety of Oxaliplatin-tegafur,Gimeracil and Oteracil Potassium and Vinorelbine-Pt in the Treatment of Advanced Triple Negative Breast Cancer [J] . Miroslav Samaržija, Lela Bitar 现代肿瘤学研究进展(英文) . 2019,第005期
• 3. Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial [J] . Qiu‑Wen Tan, Ting Luo, Hong Zheng, 癌症（英文版） . 2017,第006期
• 4. A phase II multicenter study of two different dosages of pemetrexed given in combination with cyclophosphamide as first-line treatment in patients with locally advanced or metastatic breast cancer [J] . DittrichC., SolskaE., ManikhasA., Cancer investigation . 2012,第4期
• 5. Efficacy of fulvestrant 500?mg in Chinese postmenopausal women with advanced/recurrent breast cancer and factors associated with prolonged time-to-treatment failure: A retrospective case series [J] . Huang Jian, Huang Ping, Shao Xi-ying, Medicine. . 2020,第29期
• 6. Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study) [J] . Kei Kimizuka, Kenichi Inoue, Shigenori E. Nagai, Journal of Nippon Medical School . 2019,第3期
• 7. Adjuvant Neutron Therapy in Complex Treatment of Patients with Locally Advanced Breast Cancer [C] . V. A. Lisin, V. V. Velikaya, Zh. A. Startseva, International Conference on Physics of Cancer : Interdisciplinary Problems and Clinical Applications . 2017
• 8. Boron neutron capture therapy applied to advanced breast cancers: Engineering simulation and feasibility study of the radiation treatment protocol. [D] . Sztejnberg Goncalves-Carralves, Manuel Leonardo. 2009
• 9. Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study [O] . Matthew J. Ellis, Antonio Llombart-Cussac, David Feltl, -1
• 10. Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study) [O] . Kei Kimizuka, Kenichi Inoue, Shigenori E. Nagai, 2019

• 1. CDK4/6 inhibitors in the treatment of hormone receptor-positive, HER2-negative advanced breast cancer [J] . Xue Yang . TMR药物联合治疗 . 2020,第001期
• 2. Combination of Aromatase Inhibitors with Metronomic Capecitabine: A New Chemoendocrine Treatment for Advanced Breast Cancer [J] . Wei Shi ,Xinyue Wang ,Xiwen Bi . 癌症治疗（英文） . 2019,第2期
• 3. 周剂量紫杉醇联合顺铂治疗晚期乳腺癌的临床观察 [C] . 潘荣强 ,李光明 ,文世民 . 中华医学会乳腺癌学组第五届乳腺癌重庆论坛 . 2008
• 4. 紫杉醇联合卡铂对比紫杉醇联合表阿霉素治疗局部晚期三阴性乳腺癌的Ⅱ期临床研究 [A] . 尹一 . 2013